| 磷酸二酯酶抑制剂药理学作用机制和临床应用研究进展 |
| |
| 引用本文： | 郑刚,赵智勇,秦建君,丛鑫. 磷酸二酯酶抑制剂药理学作用机制和临床应用研究进展[J]. 世界临床药物, 2021, 42(2): 149-154 |
| |
| 作者姓名： | 郑刚 赵智勇 秦建君 丛鑫 |
| |
| 作者单位： | 天津市第三中心医院分院心内科,天津300250;石药集团欧意药业有限公司,河北石家庄050051 |
| |
| 摘 要： | 磷酸二酯酶(phosphodiesteras,PDE)可降解机体细胞内环磷酸腺苷(cyclic adenosine monophosphate,cAMP)和环磷酸鸟苷(cyclic guanosine monophosphate,cGMP).PDE抑制剂可降低PDE活性,从而减弱其对cAMP和cGMP的降解能力.机体不...
|
| 关 键 词： | 磷酸二酯酶抑制剂 药理学 作用机制 |
Research progress on pharmacological mechanism and clinical application of phosphodiesterase inhibitors |
| |
| ZHENG Gang,ZHAO Zhiyong,QIN Jianjun,CONG Xin. Research progress on pharmacological mechanism and clinical application of phosphodiesterase inhibitors[J]. WORLD CLINICAL DRUGS, 2021, 42(2): 149-154 |
| |
| Authors: | ZHENG Gang ZHAO Zhiyong QIN Jianjun CONG Xin |
| |
| Affiliation: | (Department of Cardiology,Tianjin Third Central Hospital Branch,Tianjin 300250,China;Shijiazhuang Pharmaceutical Group Co.,Ltd.,Shijiazhuang 050051,Hebei Province,China) |
| |
| Abstract: | Phosphodiesteras(PDE) can degrade cyclic adenosine monophosphate(cAMP) and cyclic guanosine monophosphate(cGMP).PDE inhibitors can reduce the activity of PDE,thus weaken its ability to degrade cAMP and cGMP.There are different PDE isozymes in different parts of the body,so different subtypes of PDE inhibitors have different effects on the body.This article reviewed the pharmacological mechanism and clinical application of different PDE isozymes and their inhibition,in order to provide reference for the research and development of new drugs for related diseases. |
| |
| Keywords: | phosphodiesterase inhibitor pharmacology mechanism |
| 本文献已被 维普 万方数据 等数据库收录！ |
|
